Clinical review report: Telotristat (Xermelo) (Ipsen Biopharmaceuticals Canada Inc.)
The objective of this report is to perform a systematic review of the beneficial and harmful effects of telotristat ethyl for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose disease inadequately controlled by SSA the...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
July 2019, 2019
|
| Edition: | Version: final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of telotristat ethyl for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose disease inadequately controlled by SSA therapy alone |
|---|---|
| Physical Description: | 1 PDF file (86 pages) illustrations |